Comparison of ELISA with automated ECLIA for IL-6 determination in COVID-19 patients: An Italian real-life experience
Objectives: Coronavirus disease 2019 (COVID-19) has a wide spectrum of clinical severity. A cytokine storm is associated with COVID-19 severity. Of these, IL-6 is significantly associated with higher mortality and is also a marker for predicting disease prognosis. IL-6 may act as a target for therap...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Practical Laboratory Medicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352551724000386 |
| _version_ | 1827287959630512128 |
|---|---|
| author | Francesca Romano Luisa Lanzilao Edda Russo Maria Infantino Francesca Nencini Giovanni Cappelli Stefano Dugheri Mariangela Manfredi Alessandra Fanelli Amedeo Amedei Nicola Mucci |
| author_facet | Francesca Romano Luisa Lanzilao Edda Russo Maria Infantino Francesca Nencini Giovanni Cappelli Stefano Dugheri Mariangela Manfredi Alessandra Fanelli Amedeo Amedei Nicola Mucci |
| author_sort | Francesca Romano |
| collection | DOAJ |
| description | Objectives: Coronavirus disease 2019 (COVID-19) has a wide spectrum of clinical severity. A cytokine storm is associated with COVID-19 severity. Of these, IL-6 is significantly associated with higher mortality and is also a marker for predicting disease prognosis. IL-6 may act as a target for therapeutics and, a blockade of IL-6 function by Tocilizumab has been described as a treatment of the inflammatory process COVID-19-related. This study aims to describe our experience comparing two different methods, in detail Human IL-6 Instant ELISA and the Elecsys IL-6 based on ECLIA, for the IL-6 assessment. Design and methods: IL-6 levels from serum samples of 104 COVID-19 patients, admitted to the AOU Careggi (Hospital in Florence -Italy), were assessed by using the two above-mentioned methods, and the results were analysed through Passing-Bablok regression fit and Bland-Altman plot. Results: The regression exhibited a linear relation between the methods with a regression equation (y = - 0.13 + 0.63 x; 95 % C.I. intercept = − 0.13 to 4.55; 95 % C.I. slope = 1.03 to 1.26 with R2 = 0.89, p > 0.05), showing a positive slope. The agreement of the two methods reported a bias of −25.0 pg/mL. Thus, the two methods correlate but do not agree in terms of numeric results. Conclusions: The two assays showed good comparability. However, because of the extremely wide linear range of the ECLIA, its throughput and its capacity for immune profiling, it represents an interesting emerging technology in the immunology field. |
| first_indexed | 2024-04-24T11:21:51Z |
| format | Article |
| id | doaj.art-d4fef9faa0e14628b415974d3e80f32a |
| institution | Directory Open Access Journal |
| issn | 2352-5517 |
| language | English |
| last_indexed | 2024-04-24T11:21:51Z |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Practical Laboratory Medicine |
| spelling | doaj.art-d4fef9faa0e14628b415974d3e80f32a2024-04-11T04:41:32ZengElsevierPractical Laboratory Medicine2352-55172024-03-0139e00392Comparison of ELISA with automated ECLIA for IL-6 determination in COVID-19 patients: An Italian real-life experienceFrancesca Romano0Luisa Lanzilao1Edda Russo2Maria Infantino3Francesca Nencini4Giovanni Cappelli5Stefano Dugheri6Mariangela Manfredi7Alessandra Fanelli8Amedeo Amedei9Nicola Mucci10General Laboratory, Azienda Ospedaliero-Universitaria Careggi, Florence, ItalyGeneral Laboratory, Azienda Ospedaliero-Universitaria Careggi, Florence, ItalyDepartment of Experimental and Clinical Medicine, University of Florence, 50121, Florence, Italy; Corresponding author.Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, 50143, Florence, ItalyGeneral Laboratory, Azienda Ospedaliero-Universitaria Careggi, Florence, ItalyDepartment of Experimental and Clinical Medicine, University of Florence, 50121, Florence, ItalyDepartment of Experimental and Clinical Medicine, University of Florence, 50121, Florence, ItalyImmunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, 50143, Florence, ItalyGeneral Laboratory, Azienda Ospedaliero-Universitaria Careggi, Florence, ItalyDepartment of Experimental and Clinical Medicine, University of Florence, 50121, Florence, ItalyDepartment of Experimental and Clinical Medicine, University of Florence, 50121, Florence, ItalyObjectives: Coronavirus disease 2019 (COVID-19) has a wide spectrum of clinical severity. A cytokine storm is associated with COVID-19 severity. Of these, IL-6 is significantly associated with higher mortality and is also a marker for predicting disease prognosis. IL-6 may act as a target for therapeutics and, a blockade of IL-6 function by Tocilizumab has been described as a treatment of the inflammatory process COVID-19-related. This study aims to describe our experience comparing two different methods, in detail Human IL-6 Instant ELISA and the Elecsys IL-6 based on ECLIA, for the IL-6 assessment. Design and methods: IL-6 levels from serum samples of 104 COVID-19 patients, admitted to the AOU Careggi (Hospital in Florence -Italy), were assessed by using the two above-mentioned methods, and the results were analysed through Passing-Bablok regression fit and Bland-Altman plot. Results: The regression exhibited a linear relation between the methods with a regression equation (y = - 0.13 + 0.63 x; 95 % C.I. intercept = − 0.13 to 4.55; 95 % C.I. slope = 1.03 to 1.26 with R2 = 0.89, p > 0.05), showing a positive slope. The agreement of the two methods reported a bias of −25.0 pg/mL. Thus, the two methods correlate but do not agree in terms of numeric results. Conclusions: The two assays showed good comparability. However, because of the extremely wide linear range of the ECLIA, its throughput and its capacity for immune profiling, it represents an interesting emerging technology in the immunology field.http://www.sciencedirect.com/science/article/pii/S2352551724000386COVID-19Interleukin-6ELISAECLIA |
| spellingShingle | Francesca Romano Luisa Lanzilao Edda Russo Maria Infantino Francesca Nencini Giovanni Cappelli Stefano Dugheri Mariangela Manfredi Alessandra Fanelli Amedeo Amedei Nicola Mucci Comparison of ELISA with automated ECLIA for IL-6 determination in COVID-19 patients: An Italian real-life experience Practical Laboratory Medicine COVID-19 Interleukin-6 ELISA ECLIA |
| title | Comparison of ELISA with automated ECLIA for IL-6 determination in COVID-19 patients: An Italian real-life experience |
| title_full | Comparison of ELISA with automated ECLIA for IL-6 determination in COVID-19 patients: An Italian real-life experience |
| title_fullStr | Comparison of ELISA with automated ECLIA for IL-6 determination in COVID-19 patients: An Italian real-life experience |
| title_full_unstemmed | Comparison of ELISA with automated ECLIA for IL-6 determination in COVID-19 patients: An Italian real-life experience |
| title_short | Comparison of ELISA with automated ECLIA for IL-6 determination in COVID-19 patients: An Italian real-life experience |
| title_sort | comparison of elisa with automated eclia for il 6 determination in covid 19 patients an italian real life experience |
| topic | COVID-19 Interleukin-6 ELISA ECLIA |
| url | http://www.sciencedirect.com/science/article/pii/S2352551724000386 |
| work_keys_str_mv | AT francescaromano comparisonofelisawithautomatedecliaforil6determinationincovid19patientsanitalianreallifeexperience AT luisalanzilao comparisonofelisawithautomatedecliaforil6determinationincovid19patientsanitalianreallifeexperience AT eddarusso comparisonofelisawithautomatedecliaforil6determinationincovid19patientsanitalianreallifeexperience AT mariainfantino comparisonofelisawithautomatedecliaforil6determinationincovid19patientsanitalianreallifeexperience AT francescanencini comparisonofelisawithautomatedecliaforil6determinationincovid19patientsanitalianreallifeexperience AT giovannicappelli comparisonofelisawithautomatedecliaforil6determinationincovid19patientsanitalianreallifeexperience AT stefanodugheri comparisonofelisawithautomatedecliaforil6determinationincovid19patientsanitalianreallifeexperience AT mariangelamanfredi comparisonofelisawithautomatedecliaforil6determinationincovid19patientsanitalianreallifeexperience AT alessandrafanelli comparisonofelisawithautomatedecliaforil6determinationincovid19patientsanitalianreallifeexperience AT amedeoamedei comparisonofelisawithautomatedecliaforil6determinationincovid19patientsanitalianreallifeexperience AT nicolamucci comparisonofelisawithautomatedecliaforil6determinationincovid19patientsanitalianreallifeexperience |